148638-76-0

Basic information

• Product Name: (S)-tert-Butyl 2-((tosyloxy)Methyl)Morpholine-4-carboxylate
• Synonyms: (S)-tert-Butyl 2-((tosyloxy)Methyl)Morpholine-4-carboxylate
• CAS NO: 148638-76-0
• Molecular Weight: 371.455
• Mol File: 148638-76-0.mol

Chemical Properties

• CAS DataBase Reference: (S)-tert-Butyl 2-((tosyloxy)Methyl)Morpholine-4-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-tert-Butyl 2-((tosyloxy)Methyl)Morpholine-4-carboxylate(148638-76-0)
• EPA Substance Registry System: (S)-tert-Butyl 2-((tosyloxy)Methyl)Morpholine-4-carboxylate(148638-76-0)

Safety Data

• Hazardous Substances Data: 148638-76-0(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
(S)-tert-Butyl 2-((tosyloxy)Methyl)Morpholine-4-carboxylate is used as a versatile intermediate for the synthesis of various bioactive compounds. Its unique structure and functional groups allow for a wide range of reactions, making it a valuable asset in the development of new organic compounds.
Used in Pharmaceutical Research:
In the pharmaceutical industry, (S)-tert-Butyl 2-((tosyloxy)Methyl)Morpholine-4-carboxylate is used as a potential precursor for the synthesis of pharmaceutical agents. Its stability and reactivity make it an attractive candidate for the development of new drugs with potential therapeutic applications.
Used in Chemical Reactions:
(S)-tert-Butyl 2-((tosyloxy)Methyl)Morpholine-4-carboxylate is used as a reagent in various chemical reactions due to its tosylate group's ability to participate in substitution reactions. This property makes it a valuable tool for chemists in the synthesis of complex molecules and the development of novel chemical processes.

Upstream product

• 847805-29-2 (-)-2-chloro-N-((S)-2,3-dihydroxypropyl)acetamide 
• 847805-30-5 (6S)-6-(hydroxymethyl)morpholin-3-one 
• 24424-99-5 di-tert-butyl dicarbonate 
• 52520-62-4 (2S)-4-benzyl-2-<<(p-tolylsulfonyl)oxy>methyl>morpholine 
• 135065-72-4 (S)-N-benzyl-3-chloroacetamidopropane-1,2-diol 
• 148638-78-2 (S)-4-Benzyl-6-hydroxymethyl-morpholin-3-one 
• 135097-68-6 tert-butyl (2R)-2-[(benzyloxy)methyl]morpholine-4-carboxylate 
• 148638-77-1 N-Benzyl-2-chloro-N-((S)-2,2-dimethyl-[1,3]dioxolan-4-ylmethyl)-acetamide 
• 132073-82-6 (S)-4-Benzyl-2-(hydroxymethyl)morpholine 
• 135065-70-2 (2R)-2-[(benzyloxy)methyl]morpholine 
• 132073-83-7 (S)-morpholin-2-ylmethanol 
• 98-59-9 p-toluenesulfonyl chloride 
• 135065-76-8 tert-butyl (2S)-2-(hydroxymethyl)morpholine-4-carboxylate 
• 135065-71-3 (R)-2-hydroxymethylmorpholine-4-carboxylic acid tert-butyl ester 

Downstream Products

• 1112179-08-4 tert-butyl (S)-2-((5-(6-((3-ethyl-4-fluoro-benzyl)carbamoyl)-2-methyl-pyrimidin-4-yl)-2H-tetrazol-2-yl)methyl)morpholine-4-carboxylate 
• 1137478-36-4 (S)-tert-butyl 2-((2-chloro-5-(4-methoxyphenyl)pyridin-4-ylamino)methyl)morpholine-4-carboxylate 
• 1137478-31-9 (R)-tert-butyl 2-((2-chloro-5-(4-methoxyphenyl)pyridin-4-ylamino)methyl)morpholine-4-carboxylate 
• 1168103-91-0 (S)-5-((5-(4-methoxyphenyl)-4-((morpholin-2-ylmethyl)amino)pyridin-2-yl)amino)pyrazine-2-carbonitrile 
• 1137478-38-6 (R)-5-((5-(4-methoxyphenyl)-4-((morpholin-2-ylmethyl)amino)pyridin-2-yl)amino)pyrazine-2-carbonitrile 
• 1137478-37-5 (S)-tert-butyl 2-((2-(5-cyanopyrazin-2-ylamino)-5-(4-methoxyphenyl)pyridin-4-ylamino)methyl)morpholine-4-carboxylate 
• 1137478-34-2 (R)-tert-butyl 2-((2-(5-cyanopyrazin-2-ylamino)-5-(4-methoxyphenyl)pyridin-4-ylamino)methyl)morpholine-4-carboxylate 
• 1174913-80-4 tert-butyl (2R)-2-(aminomethyl)morpholine-4-carboxylate 
• 1489389-18-5 5-[[4-[[(2S)-morpholin-2-yl]methylamino]-5-(trifluoromethyl)-2-pyridyl]amino]pyrazine-2-carbonitrile 
• 167143-96-6 (S)-4-t-butoxycarbonyl-2-{2-[2-(3-methoxyphenyl)ethyl]phenoxymethyl}morpholine 

Relevant articles and documents

COMPOUNDS USEFUL FOR INHIBITING CDK7

CDK7 inhibitors according to the formula (I): wherein X is -CH(OH)CH3, -CHFCH3, -CF2CH3, or -CF3; Y is -CH=CH2 or C2H=C2H2; and Z is CH(CH3)

NOVEL PYRAZOLO-PYRROLO-PYRIMIDINE-DIONE DERIVATIVES AS P2X3 INHIBITORS

The present invention covers substituted Pyrazolo-pyrrolo-pyrimidine-dione (PPPD) compounds of general formula (I): in which R1, R2 and R3 are as defined herein, methods of preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of neurogenic diseases, as a sole agent or in combination with other active ingredients.

Solid dispersions containing an apoptosis-inducing agent

A pro-apoptotic solid dispersion comprises, in essentially non-crystalline form, a Bcl-2 family protein inhibitory compound of Formula I as defined herein, dispersed in a solid matrix that comprises (a) a pharmaceutically acceptable water-soluble polymeric carrier and (b) a pharmaceutically acceptable surfactant. A process for preparing such a solid dispersion comprises dissolving the compound, the polymeric carrier and the surfactant in a suitable solvent, and removing the solvent to provide a solid matrix comprising the polymeric carrier and the surfactant and having the compound dispersed in essentially non-crystalline form therein. The solid dispersion is suitable for oral administration to a subject in need thereof for treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer.

NOVEL OXOQUINOLIZINE COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF BACTERIAL INFECTION

The present invention relates to novel compounds of formula (I), wherein R1, R2, R3, R4, R5, R6 and R7 are as described herein, and their pharmaceutically 5 acceptable salt, enantiomer or diastereomer thereof, and compositions including the compounds and methods of using the compounds.

Novel Triazolopyrazine Derivatives and Use Thereof

The present invention relates to novel triazolopyrazine derivatives or a pharmaceutically acceptable salt, and a pharmaceutical composition for inhibiting c-Met tyrosine kinase activity and a pharmaceutical composition for preventing or treating hyperproliferative disorders, containing the same as active ingredients. The present invention effectively inhibits c-Met tyrosine kinase activity, thereby being able to be useful as a drug for various hyperproliferative disorders such as cancers, psoriasis, rheumatoid arthritis, diabetic retinitis, etc. related to excessive cell proliferation and growth by abnormal kinase activation.

1,3-THIAZOL-2-YL SUBSTITUTED BENZAMIDES

The present invention relates to 1,3-thiazol-2-yl substituted benzamide compounds of general formula (I) as described and defined herein, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of neurogenic disorder, as a sole agent or in combination with other active ingredients.

NOVEL TRIAZOLOPYRAZINE DERIVATIVE AND USE THEREOF

The present invention relates to a novel triazolopyrazine derivative or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition containing the same as an active ingredient for preventing or treating hyper proliferative disorder. The present invention can be useful as a therapeutic agent for various hyper proliferative disorders associated with excessive cell proliferation and growth caused by abnormal kinase activity, such as cancer, psoriasis, rheumatoid arthritis, and diabetic retinopathy, by efficiently inhibiting c-Met tyrosine kinase activity.

BIARYL AMIDE COMPOUNDS AS KINASE INHIBITORS

The present invention provides compounds of Formula (I) as described herein, and salts thereof, and therapeutic uses of these compounds for treatment of disorders associated with Raf kinase activity. The invention further provides pharmaceutical compositions comprising these compounds, and compositions comprising these compounds and a therapeutic co-agent.

5-[[4-[[MORPHOLIN-2-YL]METHYLAMINO]-5-(TRIFLUOROMETHYL)-2-PYRIDYL]AMINO]PYRAZINE-2-CARBONITRILE AND THERAPEUTIC USES THEREOF

The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to 5-[[4-[[morpholin-2-yl]methylamino]-5- (trifluoromethyl)-2-pyridyl]amino]pyrazine-2-carbonitrile compounds (referred to her

BENZAMIDE DERIVATIVES, THEIR PREPARATION AND USES IN MEDICINE THEREOF

The present invention discloses novel benzamide derivatives represented by general formula (I), their preparation, pharmaceutical compositions containing the derivatives and their use as medicament, especially as a 5-HT4 stimulator, wherein the